Table 2.
Characteristics of patients diagnosed with pure PLCIS/LCIS-PF and LCIS variant immunohistochemical profile
| Final Diagnosis | Total N=16 |
||
|---|---|---|---|
|
| |||
| PLCIS N=11 |
LCIS-PF N=5 |
||
| Imaging Presentation | |||
| Calcifications (MMG) | 7 | 2 | 9 (56.3%) |
| Enhancement (MRI) | 3 | 2 | 5 (31.2%) |
| Others (MMG or MRI) | 1 | 1 | 2 (12.5%) |
|
| |||
| Previous Breast Cancer | |||
| Yes | 3 | 2 | 5 (31.2%) |
| No | 8 | 3 | 11 (68.8%) |
|
| |||
| Type of Surgery | |||
| Excision | 8 | 4 | 12 (75%) |
| Mastectomy | 3 | 1 | 4 (25%) |
|
| |||
| Margins at Excision (N=12) | |||
| Positive | 2 | 3 | 5 (31.3%) |
| Negative | 3 | 1 | 4 (25%) |
| Close | 3 | 0 | 3 (18.7%) |
|
| |||
| Immunohistochemical Profile | |||
| E-Cadherin | Negative: 11 | Negative: 5 | Negative: 16 (100%) |
| Positive: 0 | Positive: 0 | Positive: 0 | |
|
|
|||
| Estrogen Receptor* | Negative: 2 | Negative: 0 | Negative: 2 (12.5%) |
| Positive: 9 | Positive: 5 | Positive: 14 (87.5%) | |
|
|
|||
| HER2** | Negative | Negative | Negative: 15 (93.7%) |
| Score 0: 0 | Score 0: 3 | ||
| Score 1+: 10 | Score 1+: 2 | ||
|
| |||
| Equivocal | Equivocal | Equivocal: 1 (6.3%) | |
| Score 2+: 1 | Score 2+: 0 | ||
|
| |||
| Positive | Positive | Positive: 0 | |
| Score 3+: 0 | Score 3+: 0 | ||
PLCIS, pleomorphic lobular carcinoma in situ; LCIS-PF; lobular carcinoma in situ with lobular features; MMG, mammography; MRI, magnetic resonance imaging; HER2, human epidermal growth factor receptor.
*
Estrogen receptor was regarded as positive if ≥1% of LCIS cells demonstrate positive nuclear staining by immunohistochemistry;
**
HER2/neu was scored on a 0 to 3+ scale using ASCO/CAP test guideline recommendations. (16). FISH for HER2 was not performed for the equivocal case.